Navigation Links
ViGene Biosciences Introduces World's Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses

ROCKVILLE, Md., Nov. 6, 2013 /PRNewswire-iReach/ -- ViGene Biosciences, Inc., a leading provider of viral gene-delivery systems, today announces the launch of its world's largest collection of premade human full-length cDNA ORF and miRNA adenoviruses. The collection features over 1,240 pre-packaged human miRNA precursor adenoviruses and 6,000 pre-packaged human full-length cDNA adenoviruses. Its introduction will significantly boost high throughput drug discovery, support functional genomic studies, and make life science research more efficient and cost-effective.


Recombinant adenoviruses are extremely efficient gene delivery systems that are widely used in human gene therapy and in vitro gene functional studies. Compared with lentiviral vector, transfection with adenovirus can reach 100% (vs. 30% with lentivirus), and protein expression can reach up to 10-20% of the total protein. Traditionally, adenoviral vector cloning and virus production requires up to 4-6 weeks, a complex and time-consuming process. The creation of this genome-wide premade adenoviruses collection that is readily available will benefit researchers who work with difficult-to-transfect primary cells and stem cells, as well as any other researchers who use full-length cDNA clones. 

"Our strength is not only the innovative technology for adenoviral vector production, but also the capability to create the most comprehensive collection of human full-length cDNA clones in the world," said Dr. Ying Chen, Vice President of Research and Development of ViGene Biosciences, Inc. "The biotech industry has been depending heavily on the MGC (Mammalian Gene Collection) for full-length cDNA clones, but the MGC only contains 13,000 full-length cDNA clones. Of the 19,000 unique genes (loci) in the human genome, we have systematically generated 18,000 full-length cDNA templates representing 18000 unique loci. Each of these cDNAs will be cloned into our adenoviral vector to produce ready-to-use adenoviruses." noted Dr. Chen. "We are thrilled to have this near-complete genome-wide premade adenovirus collection. It will greatly accelerate genome-wide high throughput drug screening and development, cell-based assays, and many aspects of gene function studies."

In addition to the adenoviral vectors, ViGene has also developed lentiviral and adeno-associated viral (AAV) vectors. Upon completion of the genome-wide adenovirus production, ViGene is excited to further transfer the same set of full-length cDNA ORFs into lentiviral vector and AAV vector to create an even broader premade virus collection. ViGene's largest premade virus collection will represent the next generation gene products for advancing life science research.

About ViGene Biosciences

Based in Rockville, Maryland, ViGene Biosciences, Inc., is a genomics tool company that develops cutting-edge and next generation life science research reagents to support high-throughput drug discovery and functional genomics.  Pioneering the development of quality adenovirus and other viral vector production, ViGene features the world's largest collection of human full-length cDNA ORF clones, miRNA clones, premade cDNA ORF and miRNA adenoviruses, and top-of-the-line custom services.  ViGene is committed to its mission "Quality Is Our Business," for providing the highest quality products, services and bringing the most innovative ideas for gene based research.For more information, please visit or contact ViGene by email at or call (301)-231-0600

Media Contact: Kevin Lee, ViGene Biosciences, 301-231-0600,

News distributed by PR Newswire iReach:

SOURCE ViGene Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
(Date:12/1/2015)... 1, 2015  Today, AmerisourceBergen, a ... CareFront, a first-of-its-kind population health management program focused ... Designed to be built into existing employer benefit ... resources for their care and explains how to ... tools to help patients understand their treatment options ...
(Date:12/1/2015)... Dec. 1, 2015  Booth #3506 – Claymount is featuring ... annual meeting of the Radiological Society of North ... this year. Based in the Netherlands , ... Medical Systems (NYSE: VAR ) and is one of ... and solid state automatic exposure control systems for controlling dose ...
(Date:12/1/2015)... 1, 2015 --> ... van Leeuwenhoek Hospital (NKI-AVL), among the world,s largest ... Leksell Gamma Knife® Icon™, the company,s latest generation ... --> --> With the ... treatments, Leksell Gamma Knife Icon offers greatly enhanced ...
Breaking Medicine Technology:
(Date:12/1/2015)... Los Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... the United States, today announced that its iconic bottle has won top honors in ... drinks category. The Company also announced that it has been selected as a ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the start ... scientific research and discoveries, leading us to better understand the disease’s behavior. Globally, ... affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight on ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
Breaking Medicine News(10 mins):